Resumen:

Since the advent of COVID-19 mRNA vaccines, mRNA has become one of the most promising nucleic acid therapeutics. However, a major challenge now is how to deliver mRNA to targeting cells effectively and increase mRNA expression yield but de-risk potential toxicity to expand its clinical applications beyond vaccines. In the past few years, we have been actively engaged in developing novel lipid nanoparticle (LNP) technologies and mRNA structural engineering techniques to improve the delivery, stability and the production yield of mRNA therapeutics. Compared to currently commercialized mRNA technologies, our advanced LNPs and mRNA engineering techniques enable markedly enhanced protein translation capacity and therapeutic efficacy for versatile applications, including cancer immunotherapy genome editing and protein replacement therapy.

Bio:

Dr. Ni Qianqian is a tenure-track Assistant Professor at National University of Singapore. She obtained her MD and PhD from Nanjing University, China and completed her PhD and postdoc research training at National Institutes of Health (NIH). Dr. Ni’s research is dedicated to advancing the application of nanotechnologies in RNA therapy, which has been published in prestigious journals such as Nat. Rev. Bioeng. (2025), Nat. Nanotechnol. (Accepted, 2025), Adv. Mater. (2024, 2025), Nat. Commun. (2023), Angew. Chem. Int. Ed. (2023). Dr. Ni is leading several scientific projects granted by A*Star, MOE, NMRC, NRF, Singapore.